Nordic Group BV
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nordic Group BV
The European Medicines Agency has recommended that the therapeutic indications of Keytruda and Bavencio should be expanded again.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
The business unit is transitioning from being the clinical development arm of its parent company to a full-blown commercial operation in the U.S. and Europe.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced October through November 2013.
- Hospitals, Nursing Homes, Institutions
- Large Molecule
- Other Names / Subsidiaries
- Nordic Drugs
- Nordic Pharma
- Disphar International
- Indeus Life Sciences
- Prague Clinical Services